Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

PURPOSE: The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kindler, Hedy Lee, Niedzwiecki, Donna, Hollis, Donna, Sutherland, Susan, Schrag, Deborah, Hurwitz, Herbert, Innocenti, Federico, Mulcahy, Mary Frances, O'Reilly, Eileen, Wozniak, Timothy F., Picus, Joel, Bhargava, Pankaj, Mayer, Robert J., Schilsky, Richard L., Goldberg, Richard M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917317/
https://ncbi.nlm.nih.gov/pubmed/20606091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.1386
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki